Facteurs pronostiques des lymphomes B diffus à grandes cellules au diagnostic en dehors de l’index pronostique international (notice n° 659628)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03978cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191945.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Calvani, Julien |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Facteurs pronostiques des lymphomes B diffus à grandes cellules au diagnostic en dehors de l’index pronostique international |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 30 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Le lymphome B diffus à grandes cellules (DLBCL) est le lymphome non hodgkinien de l’adulte le plus fréquent, représentant 30 à 40 % de l’ensemble des lymphomes. Le pronostic apparait très hétérogène en fonction de différents facteurs liés au patient lui-même (notamment son âge et son statut de performance) et aux caractéristiques de sa maladie. D’abord basée sur le seul stade Ann-Arbor développé en 1971, la stratification pronostique s’est ensuite enrichie avec l’index pronostique international (IPI) élaboré en 1993, et révisé en 2007 après l’introduction du rituximab (R-IPI). Depuis, de très nombreux facteurs pronostiques ont été identifiés, basés sur les caractéristiques morphologiques (aspect immunoblastique ou non), immunohistochimiques (cellule d’origine, surexpression des protéines MYC/BCL2, expression de la protéine TP53, expression du CD30, du CD5, de PD-1 et/ou PD-L1, index de prolifération), et moléculaires (remaniement des gènes MYC/BCL2/BCL6 et profil mutationnel) des DLBCL, et plus récemment à partir de l’imagerie fonctionnelle (volume tumoral métabolique total) ou de l’ADN tumoral circulant. Tous ces éléments peuvent être pris en compte dans la réflexion sur la prise en charge des patients lors des réunions de concertation pluridisciplinaire, bien que le rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone (R-CHOP) reste, en 2021, le traitement de référence des DLBCL. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Diffuse large B cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma, accounting for 30 % to 40 % of all lymphomas. The prognosis is heterogeneous, depending on various factors related to the patient (in particular age and performance status) or to the characteristics of the lymphoma. Initially based on the Ann-Arbor staging developed in 1971, the prognostic stratification was later enriched with the international prognostic index (IPI) developed in 1993, and revised in 2007 after the introduction of rituximab (R-IPI). Since then, a large number of prognostic factors have been identified, based on morphological (immunoblastic aspect or not), immunohistochemical (cell of origin, overexpression of MYC and/or BCL2 proteins, expression of the TP53 protein, expression of CD30, CD5, PD-1 and/or PD-L1, proliferation index), and molecular (rearrangement of MYC/BCL2/BCL6 genes and mutational profile) characteristics of DLBCLs, and more recently from functional imaging (total metabolic tumor volume) or circulating tumor DNA. All these elements can be taken into consideration when deciding on patient care during multidisciplinary consultation meetings, although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) still remains in 2021 the reference treatment of DLBCL. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | facteurs pronostiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MYC/BCL2/BCL6 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | volume tumoral métabolique total |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Lymphome diffus à grandes cellules B |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cellule d’origine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ADN tumoral circulant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prognosis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Diffuse large B cell lymphoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MYC/BCL2/BCL6 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | total metabolic tumor volume |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | circulating tumor DNA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cell of origin |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Meignin, Véronique |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vercellino, Laëtitia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Thieblemont, Catherine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 27 | N° Supp 1 | 2021-03-15 | p. 5-17 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2021-HS1-page-5?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2021-HS1-page-5?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux